Syngene International Limited has announced significant leadership changes effective mid-2026. Kiran Mazumdar Shaw will assume the role of Executive Chairperson, Peter Bains will step down as MD & CEO, and Siddharth Mittal will be appointed as the new MD & CEO.
Syngene International Limited has informed the exchanges of a strategic leadership reshuffle aimed at strengthening its executive management. The changes, approved by the Board and NRC, mark a new chapter for the company’s growth trajectory.
Leadership Changes At The Helm
Effective April 1, 2026, Kiran Mazumdar Shaw will transition from Non-Executive Chairperson to Executive Chairperson for a five-year term. This move underscores her continued commitment to driving innovation and global expansion.
Resignation Of Peter Bains
Peter Bains will step down as Managing Director & Chief Executive Officer effective June 30, 2026. His tenure saw Syngene consolidate its position as a leading contract research and manufacturing organization.
Appointment Of Siddharth Mittal
Siddharth Mittal, currently MD & CEO of Biocon Limited, will take charge as Syngene’s MD & CEO from July 1, 2026, for a five-year term. With extensive experience in finance, M&A, and biosimilars, he is expected to lead Syngene into new growth areas including complex peptides and generics.
Key Highlights
-
Kiran Mazumdar Shaw to become Executive Chairperson from April 1, 2026
-
Peter Bains resigns as MD & CEO effective June 30, 2026
-
Siddharth Mittal appointed MD & CEO from July 1, 2026
-
Leadership changes aligned with shareholder approval requirements
Sources: Syngene International Limited regulatory filing